PAS-004 is under clinical development by Pasithea Therapeutics and currently in Phase I for Neurofibromatoses Type I (Von Recklinghausen’s Disease). According to GlobalData, Phase I drugs for Neurofibromatoses Type I (Von Recklinghausen’s Disease) have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PAS-004’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PAS-004 overview
PAS-004 is under development for the treatment of Emery-Dreifuss muscular dystrophy, neurofibromatosis type 1,noonan syndrome, colorectal cancer and advanced solid tumors, liver and lung cancer. The drug candidate is administered through oral route. It acts by targeting mitogen-activated protein kinase 1 (MAP2K1) and mitogen-activated protein kinase 2 (MAP2K2).
It was under development for the treatment of chemo resistant ovarian cancer and dilated cardiomyopathy.
Pasithea Therapeutics overview
Pasithea Therapeutics (Pasithea) is a biotechnology company that focuses on the research and discovery of novel treatments for psychiatric and neurological disorders and central nervous system diseases. The company carries out business activities through its subsidiaries in the therapeutics and clinics business division. Its pipeline products include neurofibromatosis type 1, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS) and schizophrenia. The company’s clinics provide business support services to anti-depression clinics in the UK and the US. It operates through its subsidiaries in Portugal, the UK and the US. Pasithea is headquartered in Miami Beach, Florida, the US.
For a complete picture of PAS-004’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
